Sonnet BioTherapeutics Holdings Inc. [NASDAQ: SONN] jumped around 0.46 points on Monday, while shares priced at $2.98 at the close of the session, up 18.25%. The company report on November 30, 2020 that Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010.
Compared to recombinant human IL-12, SON-1010 demonstrated an enhanced pharmacokinetic (PK) profile that was similar to IgG antibodies.
SON-1010 continues to be well tolerated at doses far exceeding levels expected in potential future clinical trials, without producing detectable cytokine imbalances.
Sonnet BioTherapeutics Holdings Inc. stock is now -80.57% down from its year-to-date (YTD) trading value. SONN Stock saw the intraday high of $3.04 and lowest of $2.53 per share. The company’s 52-week high price is 54.60, which means current price is +33.63% above from all time high which was touched on 03/19/20.
Compared to the average trading volume of 656.71K shares, SONN reached a trading volume of 4170548 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sonnet BioTherapeutics Holdings Inc. [SONN]?
The Average True Range (ATR) for Sonnet BioTherapeutics Holdings Inc. is set at 0.18, with the Price to Sales ratio for SONN stock in the period of the last 12 months amounting to 2.34. The Price to Book ratio for the last quarter was 99.33, with the Price to Cash per share for the same quarter was set at 0.23.
How has SONN stock performed recently?
Sonnet BioTherapeutics Holdings Inc. [SONN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.61. With this latest performance, SONN shares gained by 16.86% in over the last four-week period, additionally sinking by -30.37% over the last 6 months – not to mention a drop of -81.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SONN stock in for the last two-week period is set at 64.17, with the RSI for the last a single of trading hit 70.59, and the three-weeks RSI is set at 60.69 for Sonnet BioTherapeutics Holdings Inc. [SONN]. The present Moving Average for the last 50 days of trading for this stock 2.62, while it was recorded at 2.61 for the last single week of trading, and 4.80 for the last 200 days.
Sonnet BioTherapeutics Holdings Inc. [SONN]: Deeper insight into the fundamentals
Sonnet BioTherapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.10.
Earnings analysis for Sonnet BioTherapeutics Holdings Inc. [SONN]
With the latest financial reports released by the company, Sonnet BioTherapeutics Holdings Inc. posted -8.84/share EPS, while the average EPS was predicted by analysts to be reported at -8.06/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SONN.
Insider trade positions for Sonnet BioTherapeutics Holdings Inc. [SONN]
There are presently around $1 million, or 3.30% of SONN stock, in the hands of institutional investors. The top three institutional holders of SONN stocks are: BLACKROCK INC. with ownership of 240,649, which is approximately -0.573% of the company’s market cap and around 6.40% of the total institutional ownership; VANGUARD GROUP INC, holding 88,838 shares of the stock with an approximate value of $0.27 million in SONN stocks shares; and SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC, currently with $73000.0 in SONN stock with ownership of nearly New of the company’s market capitalization.
9 institutional holders increased their position in Sonnet BioTherapeutics Holdings Inc. [NASDAQ:SONN] by around 158,020 shares. Additionally, 3 investors decreased positions by around 7,453 shares, while 5 investors held positions by with 238,595 shares. The mentioned changes placed institutional holdings at 404,068 shares, according to the latest SEC report filing. SONN stock had 7 new institutional investments in for a total of 154,717 shares, while 1 institutional investors sold positions of 4,481 shares during the same period.